Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Feb 23

PMID 23431365

Citations 36

Authors

Masakatsu Oishi

Yosuke Iizumi

Tomoyuki Taniguchi

Wakana Goi

Tsuneharu Miki

Toshiyuki Sakai

Affiliations

Soon will be listed here.

Abstract

Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic agent. Recombinant human Apo2L/TRAIL has been under clinical trials, whereas various kinds of malignant tumors have resistance to Apo2L/TRAIL. We and others have shown that several anticancer agents and flavonoids overcome resistance to Apo2L/TRAIL by upregulating death receptor 5 (DR5) in malignant tumor cells. However, the mechanisms by which these compounds induce DR5 expression remain unknown. Here we show that the dietary flavonoid apigenin binds and inhibits adenine nucleotide translocase-2 (ANT2), resulting in enhancement of Apo2L/TRAIL-induced apoptosis by upregulation of DR5. Apigenin and genistein, which are major flavonoids, enhanced Apo2L/TRAIL-induced apoptosis in cancer cells. Apigenin induced DR5 expression, but genistein did not. Using our method identifying the direct targets of flavonoids, we compared the binding proteins of apigenin with those of genistein. We discovered that ANT2 was a target of apigenin, but not genistein. Similarly to apigenin, knockdown of ANT2 enhanced Apo2L/TRAIL-induced apoptosis by upregulating DR5 expression at the post-transcriptional level. Moreover, silencing of ANT2 attenuated the enhancement of Apo2L/TRAIL-induced apoptosis by apigenin. These results suggest that apigenin upregulates DR5 and enhances Apo2L/TRAIL-induced apoptosis by binding and inhibiting ANT2. We propose that ANT2 inhibitors may contribute to Apo2L/TRAIL therapy.

Citing Articles

MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.

Guo J, Zhong L, Momeni M Cell Biol Toxicol. 2024; 40(1):77.

PMID: 39283408 PMC: 11405467. DOI: 10.1007/s10565-024-09920-2.

Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta-analysis.

Ahmadzadeh K, Dizaji S, Ramezani F, Imani F, Shamseddin J, Sarveazad A Cancer Med. 2024; 13(17):e70171.

PMID: 39254067 PMC: 11386296. DOI: 10.1002/cam4.70171.

The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

Figueira M, Carvalho T, Macario-Monteiro J, Cardoso H, Correia S, Vaz C Biomedicines. 2024; 12(8).

PMID: 39200101 PMC: 11351860. DOI: 10.3390/biomedicines12081636.

Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading.

Naponelli V, Rocchetti M, Mangieri D Int J Mol Sci. 2024; 25(10).

PMID: 38791608 PMC: 11122459. DOI: 10.3390/ijms25105569.

Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.

Sukocheva O, Neganova M, Aleksandrova Y, Burcher J, Chugunova E, Fan R Cell Commun Signal. 2024; 22(1):251.

PMID: 38698424 PMC: 11064425. DOI: 10.1186/s12964-024-01626-6.

References

Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H . Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec. 2009; 9(1):66-85. DOI: 10.1002/tcr.20170. View

Tsaytler P, Harding H, Ron D, Bertolotti A . Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011; 332(6025):91-4. DOI: 10.1126/science.1201396. View

Jang J, Choi Y, Jeon Y, Kim C . Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res. 2008; 10(1):R11. PMC: 2374967. DOI: 10.1186/bcr1857. View

Ding J, Polier G, Kohler R, Giaisi M, Krammer P, Li-Weber M . Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem. 2011; 287(1):641-649. PMC: 3249118. DOI: 10.1074/jbc.M111.286526. View

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T . The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2006; 5(4):945-51. DOI: 10.1158/1535-7163.MCT-05-0431. View

Bracarda S, Logothetis C, Sternberg C, Oudard S . Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int. 2011; 107 Suppl 2:13-20. DOI: 10.1111/j.1464-410X.2010.10036.x. View

Le Bras M, Borgne-Sanchez A, Touat Z, Sharaf el dein O, Deniaud A, Maillier E . Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 2006; 66(18):9143-52. DOI: 10.1158/0008-5472.CAN-05-4407. View

Sharaf el dein O, Mayola E, Chopineau J, Brenner C . The adenine nucleotide translocase 2, a mitochondrial target for anticancer biotherapy. Curr Drug Targets. 2011; 12(6):894-901. DOI: 10.2174/138945011795529047. View

Urusova D, Shim J, Kim D, Jung S, Zykova T, Carper A . Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev Res (Phila). 2011; 4(9):1366-77. PMC: 3244823. DOI: 10.1158/1940-6207.CAPR-11-0301. View

10.

Johnstone R, Frew A, Smyth M . The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008; 8(10):782-98. DOI: 10.1038/nrc2465. View

11.

Szliszka E, Krol W . The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev. 2010; 20(1):63-9. DOI: 10.1097/CEJ.0b013e32833ecc48. View

12.

Torkin R, Lavoie J, Kaplan D, Yeger H . Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther. 2005; 4(1):1-11. View

13.

Jin C, Park C, Cheong J, Choi B, Lee T, Lee J . Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett. 2007; 257(1):56-64. DOI: 10.1016/j.canlet.2007.06.019. View

14.

Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V . Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17(8):2506-13. DOI: 10.1200/JCO.1999.17.8.2506. View

15.

Szliszka E, Czuba Z, Jernas K, Krol W . Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci. 2009; 9(1):56-64. PMC: 2635601. DOI: 10.3390/ijms9010056. View

16.

Jang J, Jeon Y, Choi Y, Kim C . Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. Mol Cancer. 2010; 9:262. PMC: 2955620. DOI: 10.1186/1476-4598-9-262. View

17.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

18.

Hellebrand E, Varbiro G . Development of mitochondrial permeability transition inhibitory agents: a novel drug target. Drug Discov Ther. 2012; 4(2):54-61. View

19.

Walczak H, Miller R, Ariail K, Gliniak B, Griffith T, Kubin M . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2):157-63. DOI: 10.1038/5517. View

20.

Budhraja A, Gao N, Zhang Z, Son Y, Cheng S, Wang X . Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther. 2011; 11(1):132-42. PMC: 4430727. DOI: 10.1158/1535-7163.MCT-11-0343. View